Rutgers University, School of Pharmacy, New Brunswick, NJ, USA.
Expert Opin Pharmacother. 2013 Aug;14(11):1449-65. doi: 10.1517/14656566.2013.802773. Epub 2013 Jul 3.
Inflammatory disorders of the anterior surface of the eye consist of a spectrum of disorders that range from ocular allergy, dry eye syndrome (DES), and various infections. They exhibit similar pathological profiles, but have divergent immune mechanisms with some overlap. A number of novel treatments are currently being studied that capitalize on the growing understanding of underlying immunopathophysiology.
The goal of this review is to examine the emerging pipeline for noninfectious inflammatory disorders of the anterior surface of the eye - primarily allergic conjunctivitis (AC) and DES - in light of the recent basic science discoveries that have fueled their development. Novel molecules for the treatment of AC and DES from clinicaltrials.gov as well as recently filed patents for new molecular entities were reviewed from PUBMED and OVID.
Significant progress toward targeted treatments for AC and DES has become increasingly reliant on understanding the immunomodulatory and inflammatory mechanisms of the conjunctiva.
眼前部炎症性疾病包括一系列疾病，从眼部过敏、干眼症综合征 (DES) 和各种感染不等。它们表现出相似的病理特征，但具有不同的免疫机制，有些机制存在重叠。目前正在研究一些新的治疗方法，这些方法利用对潜在免疫发病机制的不断深入了解。
本综述的目的是根据最近推动其发展的基础科学发现，检查眼前部非传染性炎症性疾病（主要是过敏性结膜炎 [AC] 和 DES）的新兴药物研发管道。从 PUBMED 和 OVID 中查阅了来自 clinicaltrials.gov 的用于治疗 AC 和 DES 的新型分子以及新分子实体的最新专利。
针对 AC 和 DES 的靶向治疗取得了显著进展，越来越依赖于对结膜免疫调节和炎症机制的理解。
